MRNAModerna
Price
+93%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality shaky, a flag to check, growth steady, the market undecided.
Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of our technology platform, we are reimagining how medicines are made to transform how we treat and prevent diseases. Since our founding, our mRNA platform has enabled the development of vaccine and therapeutic candidates across infectious disease, oncology, rare disease and more. With a global team and a unique culture, driven by our values and mindsets, our mission is to deliver the greatest possible impact to people through mRNA medicines.
In the company’s own words · 10-K filed Feb 20, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Moderna (MRNA) reported revenue of $145M in Q2 2026 (quarter ended Jun 30, 2026), up 2.1% from the same quarter a year earlier. That came with a gross margin of 36% and net loss of $782M. For the full year FY2025, revenue was $1.94B (−40% year on year) and net income −$2.82B. Its largest product in Q2 2026 was COVID19 at $91M, 63% of the disclosed total, well ahead of Stand Ready Manufacturing at 21%. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 1, 2026Indenture and Notes On September 1, 2026, Moderna, Inc. (the “Company”) completed its previously announced private offering (the “Offering”) of $3,000,000,000 aggregate principal amount of 0.00% Convertible Senior Notes due 2032 (the “Notes”), including the exercise in full of the initial purchasers’ option to …Material agreement entered · Form 8-K
- Jul 31, 2026Moderna Reports Second Quarter 2026 Financial Results and Provides Business Updates.Earnings release · press release
- Jul 8, 2026On July 6, 2026, the Board of Directors (the “Board”) of Moderna, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating and Corporate Governance Committee”), appointed Michael McDonnell to the Board, effective July 8, 2026.Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2026 · $145.0MThe company’s own SEC segment disclosure.
- COVID19$91.0M63%
- Stand Ready Manufacturing$31.0M21%
- Collaboration Arrangement Including Arrangements With Affiliate$15.0M10%
- License And Royalty$3.0M2%
- RSV$3.0M2%
- Grant$2.0M1%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Biotechnology
The closest names by size in the same industry